Browse News
Filter News
Found 327 articles
-
Apellis Pharmaceuticals to Host a Fireside Chat at the 6th Annual Evercore ISI HealthCONx Conference
11/21/2023
Apellis Pharmaceuticals, Inc., announced that the company will host a fireside chat at the 6th Annual Evercore ISI HealthCONx Conference on Tuesday, November 28, 2023, at 10:00 a.m. ET.
-
Sobi to present new data at ASH 2023 Annual Meeting
11/20/2023
Sobi® will present new data at the 65th Annual Meeting of the American Society of Hematology in San Diego from the 9th to the 12th of December 2023.
-
Follow along as BioSpace keeps you up-to-date on the latest pharma and biotech layoffs.
-
Outlook Therapeutics® Adds Global Commercial Expertise with Appointment of Jedd Comiskey as Senior VP - Head of Europe
11/14/2023
Outlook Therapeutics, Inc. today announced the appointment of Jedd Comiskey as Senior VP – Head of Europe.
-
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - November 06, 2023
11/6/2023
Apellis Pharmaceuticals, Inc. announced that the company approved the grant of equity awards to 20 new employees with a grant date of November 1, 2023, as equity inducement awards outside of the company's 2017 Stock Incentive Plan and material to the employees’ acceptance of employment with the company.
-
SYFOVRE® (pegcetacoplan injection) Continued to Demonstrate Increasing Treatment Effects Over 3 Years in Patients with Geographic Atrophy (GA)
11/4/2023
Apellis Pharmaceuticals, Inc. announced data from the GALE extension study following 3 years of continuous treatment with SYFOVRE®, the first-ever FDA-approved treatment for geographic atrophy secondary to age-related macular degeneration.
-
Apellis Pharmaceuticals Reports Third Quarter 2023 Financial Results
11/1/2023
Apellis Pharmaceuticals, Inc. announced its third quarter 2023 financial results and business highlights.
-
Lexicon Strengthens Management Team With Two New Executives
10/31/2023
Lexicon Pharmaceuticals, Inc. announced that Matthew Cullen is joining the company as vice president of value and access, effective November 1, 2023, and Lisa DeFrancesco will join as head of investor relations and corporate strategy, effective November 13, 2023.
-
Apellis Pharmaceuticals to Host Conference Call on November 1, 2023, to Discuss Third Quarter 2023 Financial Results
10/25/2023
Apellis Pharmaceuticals , Inc. (Nasdaq: APLS) today announced that the company will host a conference call and webcast to discuss its third quarter 2023 financial results on Wednesday, November 1, 2023, at 8:00 a.m. ET.
-
RG6501 (OpRegen®) Phase 1/2a Results to Be Featured at Eyecelerator at 2023 American Academy of Ophthalmology (AAO) Annual Meeting
10/24/2023
RG6501 (OpRegen ® ) Phase 1/2a Results to Be Featured at Eyecelerator at 2023 American Academy of Ophthalmology (AAO) Annual Meeting.
-
The Lancet Publishes 24-Month Results from Phase 3 Studies of SYFOVRE® (pegcetacoplan injection) for Geographic Atrophy (GA)
10/20/2023
Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that The Lancet published the positive 24-month results from the Phase 3 OAKS and DERBY studies evaluating SYFOVRE ® (pegcetacoplan injection) for geographic atrophy (GA) secondary to age-related macular degeneration (AMD). SYFOVRE is the only treatment approved for use beyond 12 months in GA, a chronic disease and leading cause of vision loss.
-
Apellis to Present Positive Phase 2 NOBLE Results of Pegcetacoplan in Post-Transplant Recurrence of Primary IC-MPGN and C3G at Kidney Week
10/17/2023
Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) and Sobi® today announced that positive results from the Phase 2 NOBLE study investigating pegcetacoplan for the treatment of post-transplant recurrence of primary immune complex membranoproliferative glomerulonephritis (IC-MPGN) and C3 glomerulopathy (C3G) will be presented at the American Society of Nephrology (ASN) Kidney Week Annual Meeting.
-
Apellis Announces Preliminary U.S. Net Revenues of Approximately $74 Million for SYFOVRE® (pegcetacoplan injection) in the Third Quarter of 2023
10/5/2023
Apellis Pharmaceuticals, Inc. provided an update on the launch of SYFOVRE® for geographic atrophy secondary to age-related macular degeneration.
-
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - October 05, 2023
10/5/2023
Apellis Pharmaceuticals, Inc. announced that the company approved the grant of equity awards to seven new employees with a grant date of October 2, 2023, as equity inducement awards outside of the company's 2017 Stock Incentive Plan and material to the employees’ acceptance of employment with the company.
-
Apellis Announces U.S. FDA Approval of the EMPAVELI® Injector, a Device to Streamline Self-Administration
10/2/2023
Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the U.S. Food and Drug Administration (FDA) has approved the EMPAVELI® Injector.
-
Apnimed Adds Independent Director Paul Fonteyne, MS, MBA to Board of Directors
10/2/2023
Apnimed, Inc., a clinical-stage pharmaceutical company focused on developing oral pharmacologic therapies for the treatment of obstructive sleep apnea and related disorders, announced the appointment of Paul Fonteyne, MS, MBA, to its Board of Directors as an Independent Director.
-
Enable Injections Receives First U.S. Food and Drug Administration (FDA) Approval
10/2/2023
Enable Injections, Inc. ("Enable") today announced that the U.S. Food and Drug Administration (FDA) has approved the EMPAVELI Injector (enFuse®) for the subcutaneous delivery of EMPAVELI® (pegcetacoplan), which is commercialized in the United States by Apellis Pharmaceuticals, Inc. for adults with paroxysmal nocturnal hemoglobinuria (PNH).
-
Apellis Receives Permanent J-Code (J2781) for SYFOVRE® (pegcetacoplan injection), Effective October 1, 2023
9/25/2023
Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the U.S. Centers for Medicare & Medicaid Services (CMS) has assigned a permanent and product-specific J-code (J2781) for SYFOVRE ® (pegcetacoplan injection), the first-ever treatment for geographic atrophy (GA) secondary to age-related macular degeneration.
-
The latest data show Izervay is safe and effective in a two-year trial. Just six weeks after securing FDA approval, Astellas plans to submit it to the regulator to expand its label for a longer treatment timeframe.
-
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - September 06, 2023
9/6/2023
Apellis Pharmaceuticals, Inc., a global biopharmaceutical company and leader in complement, announced that the company approved the grant of equity awards to 5 new employees with a grant date of September 1, 2023, as equity inducement awards outside of the company's 2017 Stock Incentive Plan and material to the employees’ acceptance of employment with the company.